Standard BioTools Inc.

NasdaqGS:LAB Stock Report

Market Cap: US$1.0b

Standard BioTools Future Growth

Future criteria checks 5/6

Standard BioTools is forecast to grow earnings and revenue by 43.6% and 29.3% per annum respectively. EPS is expected to grow by 73.1% per annum. Return on equity is forecast to be 1.8% in 3 years.

Key information

43.6%

Earnings growth rate

73.1%

EPS growth rate

Life Sciences earnings growth16.3%
Revenue growth rate29.3%
Future return on equity1.8%
Analyst coverage

Low

Last updated29 Feb 2024

Recent future growth updates

Recent updates

Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

Mar 06
Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable

Feb 17
Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable

Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?

Jan 12
Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?

Is Standard BioTools (NASDAQ:LAB) A Risky Investment?

Aug 13
Is Standard BioTools (NASDAQ:LAB) A Risky Investment?

Fluidigm Corporation: Investment Opportunity

Jan 26

Does Fluidigm (NASDAQ:FLDM) Have A Healthy Balance Sheet?

Dec 15
Does Fluidigm (NASDAQ:FLDM) Have A Healthy Balance Sheet?

Is Fluidigm (NASDAQ:FLDM) A Risky Investment?

Jul 27
Is Fluidigm (NASDAQ:FLDM) A Risky Investment?

Fluidigm Corporation: Discounted Life Sciences Instrument Developer Offers Compelling Entry Point

Jun 20

Fluidigm gains after report that activist takes 11% stake, may push for unit sale

May 11

Fluidigm Corporation 2021 Q1 - Results - Earnings Call Presentation

May 07

Fluidigm Corporation (NASDAQ:FLDM) Analysts Just Slashed This Year's Estimates

Feb 15
Fluidigm Corporation (NASDAQ:FLDM) Analysts Just Slashed This Year's Estimates

Earnings and Revenue Growth Forecasts

NasdaqGS:LAB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026300925341
12/31/2025235-69-45-361
12/31/2024200-161-125-1171
12/31/2023106-75-46-43N/A
9/30/2023105-76-52-48N/A
6/30/2023105-84-65-62N/A
3/31/202397-131-86-82N/A
12/31/202298-190-93-89N/A
9/30/2022109-179-81-77N/A
6/30/2022112-163-66-62N/A
3/31/2022124-117-54-47N/A
12/31/2021131-59-57-44N/A
9/30/2021137-68-64-41N/A
6/30/2021148-60-58-36N/A
3/31/2021143-56-43-24N/A
12/31/2020138-53-28-15N/A
9/30/2020126-48-20-17N/A
6/30/2020113-55-21-17N/A
3/31/2020115-55-23-19N/A
12/31/2019117-65-38-35N/A
9/30/2019117-67-32-30N/A
6/30/2019120-69-31-30N/A
3/31/2019118-71-30-29N/A
12/31/2018113-59-26-25N/A
9/30/2018108-55-24-24N/A
6/30/2018104-56-29-28N/A
3/31/2018102-57-33-32N/A
12/31/2017102-61-26-24N/A
9/30/201799-68N/A-35N/A
6/30/201797-72N/A-41N/A
3/31/2017101-73N/A-40N/A
12/31/2016104-76N/A-39N/A
9/30/2016110-71N/A-33N/A
6/30/2016117-61N/A-32N/A
3/31/2016117-57N/A-33N/A
12/31/2015115-53N/A-35N/A
9/30/2015117-51N/A-34N/A
6/30/2015118-56N/A-30N/A
3/31/2015117-53N/A-22N/A
12/31/2014116-53N/A-23N/A
9/30/2014104-47N/A-16N/A
6/30/201492-37N/A-8N/A
3/31/201482-28N/A-11N/A
12/31/201371-17N/A-2N/A
9/30/201366-15N/A-8N/A
6/30/201360-15N/A-10N/A
3/31/201356-16N/A-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LAB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: LAB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: LAB is expected to become profitable in the next 3 years.

Revenue vs Market: LAB's revenue (29.3% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: LAB's revenue (29.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: LAB's Return on Equity is forecast to be low in 3 years time (1.8%).


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.